Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer

R. T. Morris; R. D. Alvarez; J. Malone; C. Bryant; S. J. Andrews; L. Kilgore; G. D. Phibbs; L. Heilbrun; A. R. Munkarah

doi:10.1200/JCO.2005.23.16_SUPPL.5058

Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer

R. T. Morris
, R. D. Alvarez
, J. Malone
, C. Bryant
, S. J. Andrews
, L. Kilgore
, G. D. Phibbs
, L. Heilbrun
, A. R. Munkarah

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	23
DOIs	https://doi.org/10.1200/JCO.2005.23.16_SUPPL.5058
State	Published - Jun 1 2005

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2005.23.16_SUPPL.5058License: Unspecified

Cite this

@article{745878cae90f4e91a041cc7007434836,

title = "Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer",

author = "Morris, \{R. T.\} and Alvarez, \{R. D.\} and J. Malone and C. Bryant and Andrews, \{S. J.\} and L. Kilgore and Phibbs, \{G. D.\} and L. Heilbrun and Munkarah, \{A. R.\}",

note = "5058 Background: Topotecan 1.5 mg/m2 on days 1 through 5 of a 21-day cycle is a standard treatment for recurrent ovarian cancer. However, the optimal dosing regimen for topotecan has not yet been established. Therefore, in a prospective, multicenter phase II study, we investigated the safety and activity of weekly topotecan in patients (pts) with platinum-sensitive relapsed epithelial ovarian or peritoneal cancer.",

year = "2005",

month = jun,

day = "1",

doi = "10.1200/JCO.2005.23.16\_SUPPL.5058",

language = "American English",

volume = "23",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer

AU - Morris, R. T.

AU - Alvarez, R. D.

AU - Malone, J.

AU - Bryant, C.

AU - Andrews, S. J.

AU - Kilgore, L.

AU - Phibbs, G. D.

AU - Heilbrun, L.

AU - Munkarah, A. R.

N1 - 5058 Background: Topotecan 1.5 mg/m2 on days 1 through 5 of a 21-day cycle is a standard treatment for recurrent ovarian cancer. However, the optimal dosing regimen for topotecan has not yet been established. Therefore, in a prospective, multicenter phase II study, we investigated the safety and activity of weekly topotecan in patients (pts) with platinum-sensitive relapsed epithelial ovarian or peritoneal cancer.

PY - 2005/6/1

Y1 - 2005/6/1

UR - https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.5058

U2 - 10.1200/JCO.2005.23.16_SUPPL.5058

DO - 10.1200/JCO.2005.23.16_SUPPL.5058

M3 - Article

VL - 23

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer

Disciplines

Access to Document

Other files and links

Cite this